Pharmacyclics (PCYC) Likely to See Upside Near-Term, Says RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Remains Positive on Pharmacyclics (PCYC) Following Imbruvica Update; Maintains 'Buy' Rating
January 14, 2015 7:52 AM ESTRoth Capital affirms Pharmacyclics (Nasdaq: PCYC) at Buy with a price target of $188 following an impressive update on... More
Baird Increasingly Bullish on Pharmacyclics (PCYC); Top Pick for 2015
January 13, 2015 8:04 AM ESTBaird analyst Brian Skorney reiterated an Outperform rating and $173 price target on Pharmacyclics (NASDAQ: PCYC) saying he is increasingly bullish on Imbruvica performance and 2015 guidance.
Skorney commented, "As one of our top picks for 2015, we anticipated that Pharmacyclics would continue to deliver on the... More
Pharmacyclics (PCYC) Sees FY15 Net Product Revenue of $1B for IMBRUVICA
January 12, 2015 5:46 PM ESTPharmacyclics, Inc. (NASDAQ: PCYC) today provided its preliminary unaudited 2014 U.S. net product revenue results and 2015 U.S. net product revenue outlook at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. For the fiscal year ended December 31, 2014, U.S. net product revenue for IMBRUVICA® (ibrutinib) is expected to be approximately $492 million. For the fourth quarter of 2014,... More
